IL6R and rheumatoid arthritis: Significantly differential expression of miR-26b, miR-29, miR-451, and miR-522 in the groups of responders and non-responders to olokizumab treatment, as well as their tight connection with IL-6/IL-6R signaling pathway make them a potential therapeutic response biomarker, which could be useful for personalized choice of therapy for RA patients.